There's no denying it - Alzheimer's disease is a brutal thief of memories. But there's finally some good news on the horizon! Recent years have seen the FDA approval of several new drugs that slow the progression of this debilitating disease.
New Weapons in the Fight:
Donanemab (Kisunla™): This one might hit close to home! Developed by Eli Lilly, a Hoosier company through and through, donanemab is an intravenous treatment that specifically targets the beta-amyloid plaques associated with Alzheimer's. Early studies show a promising 35% slowdown in cognitive decline for those in the early stages of the disease!
Lecanemab (Leqembi): Another recent FDA approval, Leqembi works similarly to donanemab by attacking beta-amyloid plaques. While both drugs offer significant benefits, donanemab has the potential advantage of stopping treatment once the plaques are cleared. Another advantage is that Lecanemab requires infusions every two weeks, whereas donanemab is administered only once a month.
Important Considerations:
Early Intervention is Key: These medications seem most effective when administered in the early stages of Alzheimer's.
Weighing the Benefits and Risks: As with any medication, there are potential side effects, including brain swelling and bleeding. It's crucial to discuss these risks and benefits with your doctor.
Cost Considerations: These new treatments can be expensive, and insurance coverage varies. Make sure to explore all options with your healthcare provider.
A Beacon of Hope:
While there's still no cure for Alzheimer's, these new drugs offer a significant step forward. They can potentially help people maintain their independence and quality of life for longer. With continued research, the future for Alzheimer's treatment looks brighter!
Remember: If you or someone you know is experiencing memory changes, talk to a healthcare professional for a proper diagnosis and discuss potential treatment options.
Let's keep fighting for a future free from Alzheimer's!
Comments